| Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix (NCT06771596) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-05-12 |
| A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin (NCT04850040) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-05-06 |
| Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC (NCT04791176) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-04-12 |
| Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique projecT (NCT04822792) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-03-23 |
| Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT (NCT04709380) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-03-02 |
| MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02) (NCT05183074) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-02-01 |
| An MRI-Based Study of Intelligent Pathological Subtyping and Grading of Renal Tumors (NCT07743749) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-01-01 |
| Multi-Centre, Observational Study on Safety of Bevacizumab Biosimilars in Clinical Practice Among Chinese Patients (NCT05009017) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-01-01 |
| MRI-guided Lateral Lymph Node Dissection in Rectal Cancer (NCT04850027) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-01-01 |
| To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer (NCT04671303) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-01-01 |
| Perioperative and Postoperative Circulating Tumor Cell Monitoring in Different Stage of NSCLC (NCT07186855) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-01-01 |
| Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC (NCT06034964) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-11-01 |
| Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC (NCT04500704) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-10-01 |
| Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer (NCT04821765) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-10-01 |
| Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation (NCT04500717) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-10-01 |
| Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer (NCT04506242) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-09-15 |
| Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer (NCT04498793) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-09-01 |
| PLATFORM Study of Precision Medicine for Rare Tumors (NCT04423185) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-08-15 |
| A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer (NCT04543695) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-08-15 |
| Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor (NCT06540937) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-07-01 |
| Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma (NCT07147361) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-05-28 |
| Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients (NCT04320979) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-05-08 |
| Preoperative IMRT With Anlotinib and Penpulimab for Localized Sarcoma （SPARE-01） (NCT05167994) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-05-01 |
| Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine (NCT04389073) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-04-01 |
| Mediastinoscopy-assisted Transhiatal Esophagectomy Versus Thoraco-laparoscopic Esophagectomy for Esophageal Cancer (NCT04125849) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-04-01 |
| Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer (NCT04213937) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-01-31 |
| Magnetic Resonance Imaging-guided Adaptive Radiotherapy for Large Brain Metastases (NCT06405256) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-01-03 |
| Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy (NCT07256002) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-01-01 |
| A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer (NCT04207918) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2019-11-14 |
| Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers (NCT06255197) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2019-11-04 |
| Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma (NCT04099589) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2019-10-01 |
| Chemoradiotherapy in Unresectable Esophageal Cancer (NCT04278287) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2019-10-01 |
| Prophylactic PEG-rhG-CSF During cCRT in LA-NSCLC (NCT06958614) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2019-09-02 |
| Taxane Induced Peripheral Neuropathy in Chinese Patients With Breast Cancer (NCT04068090) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2019-08-23 |
| Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection (NCT03839550) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2019-02-15 |
| The Influence of Treatment Position (Prone vs. Supine) on Whole Breast Target (NCT05609058) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2019-01-01 |
| Short-term and Long-term Outcomes of Colorectal Cancer Treated With Natural Orifice Specimen Extraction Surgery : a National Registry-based Study (NCT06350370) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2019-01-01 |
| Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer (NCT03775928) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2018-12-18 |
| MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer (NCT03714490) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2018-10-23 |
| A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP） (NCT03137368) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2018-08-09 |
| Diagnostic Significance of CTCs in Patients With Thyroid Nodules (Circulating Tumor Cells) (NCT03772496) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2018-07-25 |
| Accelerated Partial Breast Irradiation With IMRT in Early Breast Cancer (NCT03583580) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2018-07-19 |
| Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma (NCT03535259) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2018-05-08 |
| Daytime Variation of Complication in Gastric and Pancreatic Surgery (NCT03383562) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2018-01-01 |
| A Prospective Study of Hypothyroidism After Radiotherapy for Breast Cancer (NCT04528225) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2017-11-15 |
| Perioperative Electroacupuncture After Operation (NCT03291561) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2017-08-01 |
| Perioperative Electroacupuncture for Gastric Cancer Patients After Gastrectomy (NCT03291574) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2017-07-29 |
| Randomized Trial of Accelerated Partial Breast Irradiation (NCT03583619) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2017-07-19 |
| Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer (NCT05283616) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2017-05-15 |
| Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection (NCT03575806) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2017-01-09 |
| Application Software in Dosage Adjustment for Advanced Cancer Patients With Pain (NCT03016364) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2017-01-01 |
| Apatinib for Advanced Non-squamous Head and Neck Cancer (NCT02989259) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2016-12-01 |
| The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer (NCT02943252) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2016-10-01 |
| MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy (NCT02988921) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2016-10-01 |
| A Multicenter, Randomized, Case-control Study of Unilateral vs Bilateral Neck Dissection for cN0 Supraglottic Laryngeal Cancer (NCT03392220) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2016-10-01 |
| Single-port, Two-port Versus Three-port VATS on Non-small Cell Lung Cancer (NCT02992353) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2016-07-01 |
| Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC (NCT02688036) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2016-02-01 |
| IORT Followed by CCRT or SBRT for Locally Advanced Pancreatic Cancer (NCT02734680) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2016-02-01 |
| Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR (NCT02691871) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2016-02-01 |
| Safety and Feasibility of Laparoscopic Intracorporeal Anastomosis for Colorectal Surgery- A Multiple Center Real World Study (NCT05911152) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2016-01-01 |
| HA-WBRT-SIB for Brain Metastasis of Lung Cancer (NCT06289023) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2016-01-01 |
| IORT Versus CCRT for Pancreatic Cancer (NCT02981641) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2015-12-01 |
| Safety Study of Totally Laparoscopic Resection With Natural Orifice Specimen Extraction (NOSE) for Rectosigmoid Cancer (NCT02635503) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2015-11-01 |
| Research on the Combined-Modality Treatment Model of Bladder Preservation in Muscular Invasive Bladder Cancer (NCT02861196) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2015-09-01 |
| Translational Research on Locally Advanced Pancreatic Adenocarcinoma (NCT03009253) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2015-07-01 |
| Uniportal Versus Triportal Thoracoscopic Lobectomy and Sublobectomy for Early Stage Lung Cancer (NCT02933294) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2015-05-01 |
| Constructing a Multimodal Imaging System to Predict the Risk of Heterochronous Metastasis of Rectal Cancer (NCT06293612) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2015-01-01 |
| Quantitative Evaluation of the Impact of Relaxing Eligibility Criteria for Lung Cancer Based on Real-world Data (NCT06314542) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2013-01-01 |
| Randomized Study of Hypofractionated and Conventional Fractionation Radiotherapy After Breast Conservative Surgery (NCT01413269) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2010-06-01 |
| Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer (NCT01024712) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2009-05-01 |
| A Multicenter Study on the Safety and Functionality Evaluation of Anastomotic Redo Surgery (NCT07279961) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2006-05-01 |
| The Factors Influencing the Success of Redo Surgery and Anal Function for Anastomosis Failure or Local Tumor Recurrence (NCT07440888) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2006-03-01 |
| Neoadjuvant Treatment Modalities in Esophageal Cancer (NCT04821843) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2002-01-01 |
| Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer (NCT04821778) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2002-01-01 |